(VIANEWS) – Air Transport Services Group (ATSG), Boston Scientific (BSX), Anthem (ANTM) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Air Transport Services Group (ATSG)

17.7% sales growth and 19.69% return on equity

Air Transport Services Group, Inc., through its subsidiaries, engages in the aircraft leasing and air cargo transportation services in the United States and internationally.

Air Transport Services Group’s sales growth this year is anticipated to be 9.4% and 9.3% for next year.

Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 1.65B for the twelve trailing months.

Volume

Today’s last reported volume for Air Transport Services Group is 389024 which is 17.42% below its average volume of 471139.

Air Transport Services Group’s sales growth for the next quarter is 17.7%. The company’s growth estimates for the present quarter and the next is 42.1% and 105.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.69%.

Volatility

Air Transport Services Group’s last day, last week, and last month’s current intraday variation average was 4.99%, 4.12%, and 1.82%, respectively.

Air Transport Services Group’s highest amplitude of average volatility was 4.28% (day), 5.33% (last week), and 3.14% (last month), respectively.

Air Transport Services Group’s Stock Yearly Top and Bottom Value

Air Transport Services Group’s stock is valued at $26.49 at 15:22 EST, way below its 52-week high of $32.43 and way higher than its 52-week low of $21.42.

Air Transport Services Group’s Moving Average

Air Transport Services Group’s worth is higher than its 50-day moving average of $25.80 and above its 200-day moving average of $26.14.

2. Boston Scientific (BSX)

17.5% sales growth and 3.69% return on equity

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

Boston Scientific’s sales growth this year is anticipated to be 21.2% and 7.9% for next year.

Year-on-year quarterly revenue growth grew by 53.6%, now sitting on 11.2B for the twelve trailing months.

Volume

Today’s last reported volume for Boston Scientific is 3623650 which is 48.52% below its average volume of 7040110.

Boston Scientific’s sales growth is a negative 0% for the ongoing quarter and 17.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 8.1% and 91.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.69%.

Volatility

Boston Scientific’s last day, last week, and last month’s current intraday variation average was 3.83%, 2.19%, and 1.20%, respectively.

Boston Scientific’s highest amplitude of average volatility was 3.90% (day), 3.35% (last week), and 2.50% (last month), respectively.

Boston Scientific’s Stock Yearly Top and Bottom Value

Boston Scientific’s stock is valued at $39.27 at 15:22 EST, way below its 52-week high of $46.29 and way above its 52-week low of $32.99.

Boston Scientific’s Moving Average

Boston Scientific’s value is below its 50-day moving average of $43.43 and below its 200-day moving average of $43.52.

Previous days news about Boston Scientific(BSX)

  • According to Business Insider on Tuesday, 30 November, "Before that, Dr. Varawalla was Senior Vice President and Head of Clinical Development at BTG International plc, where she led a global team responsible for clinical development of the company’s product portfolio across both pharmaceutical and medical device business units before it was acquired by Boston Scientific for $4.4 billion in 2019."
  • According to Business Insider on Tuesday, 30 November, "Those favorites, all rated "Outperform," are Stryker (price target of $311), Edwards Lifesciences ($130), Boston Scientific ($54), Abbott Laboratories ($138), and Globus Medical ($95)."

3. Anthem (ANTM)

15.2% sales growth and 15.84% return on equity

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States.

Anthem’s sales growth this year is anticipated to be 13.6% and 9.5% for next year.

Year-on-year quarterly revenue growth grew by 15%, now sitting on 133.88B for the twelve trailing months.

Volume

Today’s last reported volume for Anthem is 1836770 which is 65.07% above its average volume of 1112670.

Anthem’s sales growth for the next quarter is 15.2%. The company’s growth estimates for the current quarter and the next is 52.4% and 105.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.84%.

Volatility

Anthem’s last day, last week, and last month’s current intraday variation average was 1.23%, 1.14%, and 1.14%, respectively.

Anthem’s highest amplitude of average volatility was 2.89% (day), 3.72% (last week), and 2.36% (last month), respectively.

Anthem’s Stock Yearly Top and Bottom Value

Anthem’s stock is valued at $0.00 at 15:22 EST, below its 52-week low of $286.04.

Anthem’s Moving Average

Anthem’s worth is under its 50-day moving average of $402.49 and below its 200-day moving average of $388.22.

Previous days news about Anthem(ANTM)

  • According to Benzinga on Tuesday, 30 November, "It also entered into a partnership with United Way, Anthem Inc., and JPMorgan Chase in December 2020, with the goal of providing 60 million trips to and from COVID-19 vaccination sites for low-income and at-risk communities."
  • Landsea homes expands Texas homebuilding portfolio by acquiring final remaining lots in anthem master planned community. According to Business Insider on Thursday, 2 December, "All homes at Anthem will be the first in Texas to be equipped with Landsea Homes’ High Performance Home features, including smart home automation technology utilized by the Apple HomeKit™ environment. ", "At full buildout, Anthem will include approximately 1,500 single-family homes, an elementary school, amenity center and limited commercial space."

4. Luxfer Holdings PLC (LXFR)

11.8% sales growth and 16.32% return on equity

Luxfer Holdings PLC, a materials technology company, designs, manufactures, and supplies high-performance materials, components, and high-pressure gas cylinders for transportation, defense and emergency response, healthcare, and general industrial end-market applications.

Luxfer Holdings PLC’s sales growth this year is expected to be 13.2% and 6.7% for next year.

Year-on-year quarterly revenue growth grew by 29.2%, now sitting on 344M for the twelve trailing months.

Volume

Today’s last reported volume for Luxfer Holdings PLC is 73229 which is 12.92% below its average volume of 84101.

Luxfer Holdings PLC’s sales growth for the next quarter is 11.8%. The company’s growth estimates for the present quarter and the next is a negative 0% and negative -3.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.32%.

Volatility

Luxfer Holdings PLC’s last day, last week, and last month’s current intraday variation average was 0.19%, 1.35%, and 2.47%, respectively.

Luxfer Holdings PLC’s highest amplitude of average volatility was 1.90% (day), 2.47% (last week), and 3.87% (last month), respectively.

Luxfer Holdings PLC’s Stock Yearly Top and Bottom Value

Luxfer Holdings PLC’s stock is valued at $-0.35 at 15:22 EST, way below its 52-week low of $14.98.

Luxfer Holdings PLC’s Moving Average

Luxfer Holdings PLC’s worth is way under its 50-day moving average of $20.81 and way below its 200-day moving average of $21.00.

5. ABIOMED (ABMD)

11.1% sales growth and 11.62% return on equity

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.

ABIOMED’s sales growth this year is anticipated to be 20.4% and 15.9% for next year.

Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 973.64M for the twelve trailing months.

Volume

Today’s last reported volume for ABIOMED is 37621 which is 82.76% below its average volume of 218327.

ABIOMED’s sales growth is a negative 0% for the current quarter and 11.1% for the next. The company’s growth estimates for the present quarter and the next is a negative 28.1% and negative -9.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.62%.

Volatility

ABIOMED’s last day, last week, and last month’s current intraday variation average was 2.97%, 2.61%, and 1.84%, respectively.

ABIOMED’s highest amplitude of average volatility was 6.39% (day), 4.84% (last week), and 3.91% (last month), respectively.

ABIOMED’s Stock Yearly Top and Bottom Value

ABIOMED’s stock is valued at $306.79 at 15:22 EST, way below its 52-week high of $387.40 and way higher than its 52-week low of $254.41.

ABIOMED’s Moving Average

ABIOMED’s value is way below its 50-day moving average of $342.12 and below its 200-day moving average of $324.98.

6. PacWest Bancorp (PACW)

9.3% sales growth and 15.87% return on equity

PacWest Bancorp operates as the bank holding company for Pacific Western Bank that provides various banking products and services.

PacWest Bancorp’s sales growth this year is expected to be 10.4% and 9.8% for next year.

Year-on-year quarterly revenue growth grew by 80.3%, now sitting on 1.39B for the twelve trailing months.

Volume

Today’s last reported volume for PacWest Bancorp is 484477 which is 29.53% below its average volume of 687523.

PacWest Bancorp’s sales growth for the next quarter is 9.3%. The company’s growth estimates for the present quarter and the next is 2% and negative -22%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.87%.

Volatility

PacWest Bancorp’s last day, last week, and last month’s current intraday variation average was 0.12%, 0.78%, and 1.28%, respectively.

PacWest Bancorp’s highest amplitude of average volatility was 1.33% (day), 2.03% (last week), and 2.47% (last month), respectively.

PacWest Bancorp’s Stock Yearly Top and Bottom Value

PacWest Bancorp’s stock is valued at $49.24 at 15:22 EST, under its 52-week high of $50.42 and way higher than its 52-week low of $23.14.

PacWest Bancorp’s Moving Average

PacWest Bancorp’s value is above its 50-day moving average of $47.04 and way above its 200-day moving average of $42.60.

LEAVE A REPLY

Please enter your comment!
Please enter your name here